Sedation of remimazolam besylate during induction of transcatheter aortic valve implantation

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200056842

Enrollment

Unknown

Registered

2022-02-19

Start date

2022-02-07

Completion date

Unknown

Last updated

2023-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Experimental group:The anesthesia was induced with 0.3mg/kg remimazolam besylate

Control group:Anesthesia induction was performed with 0.2mg/kg etomidate

Eligibility

Sex/Gender

All

Age

35 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Aged 35-90 years, no gender limit; 2. American Society of Anesthesiologists Classification (ASA) ?-?; 3. Transcatheter aortic valve implantation; 4. Patients voluntarily participated in the study and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with known allergy to remazolam besylate or with previous history of severe allergy and family history; 2. Long-term use of narcotic analgesics, sedatives or non-steroidal anti-inflammatory drugs; 3. Opioid dependent or opioid tolerant; 4. Patients with severe lung, liver and kidney dysfunction; 5. Patients with severe arrhythmias; 6. Patients with acute myocardial infarction; 7. Emergency surgery; 8. The investigator deemed it inappropriate to participate in the clinical study.

Design outcomes

Primary

Measure	Time frame
Bispectral index;Mean arterial pressure;Heart rate;Cardiac index;Stroke volume variation;Mini-mental state examination;	—

Countries

China

Contacts

Public ContactMa Jun

majun7689@163.com+86 13811031060

Outcome results